Loading... Please wait...


Our Newsletter

TG101348 (SAR302503) | JAK2 inhibitor

  • TG101348 (SAR302503).jpg
  • TG101348 (SAR302503), 400x400px, png
Catalog #:

Product Description

TG101348 is an orally-available, aminopyrimidine-based inhibitor of JAK2 and JAK2V617F at an IC50 of 3 nM, with marked selectivity over JAK3 (IC50 >1 uM). [1, 2] TG101348 inhibits proliferation of HMC-1.1 and HMC-1.2 cells at IC50s of 740 and 407 nM, respectively. [1]

In a UT7/EPO cell line, TG101348 inhibited STAT5 phosphorylation much more potently at lower concentrations than known JAK2/3 inhibitor AG490 (600 nM vs 100 uM). In the same study, TG101348 inhibited AKT phosphorylation while reducing GATA-1 S310 phosphorylation. [2]

In human erythroleukemia and Ba/F3-JAK2V617F cells, TG101348 inhibited the cytokine-independent growth at IC50s of 300 and 580 nM, respectively. [3]

TG101348 induces apoptosis in both HEL and Ba/F3 JAK2V617F cells, but not in normal human dermal fibroblasts at concentrations up to 10 uM; antiproliferative IC50 against fibroblasts is > 5 uM.

Technical information:

Chemical Formula:   C27H36N6O3S
CAS #:   936091-26-8
Molecular Weight:   524.68
Purity:   >98%
Appearance:   Pale Yellow
Chemical Name:   N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide
Solubility:   Up to 100mM in DMSO
Synonyms:   TG101348, TG-101348, SAR302503

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. Lasho et al., Inhibition of JAK-STAT signaling by TG101348: a novel mechanism for inhibition of KITD816V-dependent growth in mast cell leukemia cells. Leukemia, 2010, 24, 1378-1380. Pubmed ID: 20485374
2. Geron et al., Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. Cancer Cell, 2008, 13(4), 321-330. Pubmed ID: 18394555
3. Lasho et al., TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients. Leukemia, 2008, 22, 1790-1792. Pubmed ID: 18354492
4. Wernig et al., Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 2008, 13(4), 311-320. Pubmed ID: 18394555

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the TG101348 (SAR302503) | JAK2 inhibitor to your wish list.

You Recently Viewed...